AbbVie (NYSE:ABBV) said that a phase 3b/4 head-to-head trial pitting Rinvoq (upadacitinib) against Humira (adalimumab) in rheumatoid arthritis demonstrated the former’s superiority over the latter.
Results from the SELECT-SWITCH trial found that a significantly higher proportion of patients who received Rinvoq achieved low disease activity, defined as Disease Activity Score 28 C-reactive Protein [DAS28-CRP]≤3.2, the primary endpoint, and remission, defined as DAS28-CRP<2.6, the secondary endpoint, compared to Humira.
Data showed that 43.3% of those on Rinvoq achieved DAS28-CRP≤3.2 compared to 22.4% of patients on Humira. For the secondary endpoint, 28.4% of patients receiving Rinvoq achieved DAS28-CRP<2.6 compared to 14.5% of patients on Humira.
Rinvoq is known as a JAK inhibitor while Humira is considered a TNF blocker. Humira is also available as a generic biosimilar.
